# HNRNPA2B1 confers immune escape of non-small cell lung cancer through targeting lactate/ferroptosis

**Authors:** Ye Zhang, Yeye Chen, Jiaqi Zhang, Xin Du, Cheng Huang

PMC · DOI: 10.1038/s41419-025-08232-5 · 2025-11-21

## TL;DR

This study shows how HNRNPA2B1 helps non-small cell lung cancer cells avoid immune detection and resist cell death through m6A modification and lactate production.

## Contribution

The study reveals a novel mechanism by which HNRNPA2B1 promotes immune escape and ferroptosis resistance in NSCLC via m6A modification of LDHA mRNA.

## Key findings

- HNRNPA2B1 high-expression impairs CD8+ T cell-mediated killing and promotes immune escape in NSCLC.
- HNRNPA2B1 stabilizes LDHA mRNA, increases lactate accumulation, and reduces IFN-γ secretion by CD8+ T cells.
- IFN-γ induces ferroptosis in NSCLC cells, but this is counteracted by HNRNPA2B1 activity.

## Abstract

Immune escape and ferroptosis resistance contribute to non-small cell lung cancer (NSCLC) carcinogenesis. This study aimed to investigate the role of N6-methyladenosine (m6A) reader heterogeneous nuclear ribonucleoprotein A2B1 (HNRNPA2B1) in NSCLC immune escape and ferroptosis resistance. HNRNPA2B1 expression was clinically elevated both in the NSCLC samples and single-cell transcriptome sequencing (scRNA-Seq). In vitro co-culture with activated CD8+ T cells, HNRNPA2B1 high-expression hampered the CD8+ T cell-mediated killing effect and accelerated the immune escape. Besides, the enforced HNRNPA2B1 high-expression alleviated the ferroptosis. Furthermore, HNRNPA2B1 targeted the LDHA mRNA m6A modified site to enhance LDHA mRNA stability and lactate accumulation, thereby assisted NSCLC cells to evade CD8+ T antitumor immunity and reduced IFN-γ secretion by CD8+ T. Furthermore, IFN-γ could stimulate ferroptosis of NSCLC cells. Taken together, these findings revealed an important role for HNRNPA2B1 on NSCLC immune escape and ferroptosis resistance, which provided novel insight into m6A modification in NSCLC.

## Linked entities

- **Genes:** HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) [NCBI Gene 3181], LDHA (lactate dehydrogenase A) [NCBI Gene 3939]
- **Proteins:** HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1)
- **Diseases:** non-small cell lung cancer (MONDO:0005233), NSCLC (MONDO:0005233)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) [NCBI Gene 3181] {aka HNRNPA2, HNRNPB1, HNRPA2, HNRPA2B1, HNRPB1, IBMPFD2}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}
- **Diseases:** carcinogenesis (MESH:D063646), NSCLC (MESH:D002289)
- **Chemicals:** m6A (MESH:C005955), lactate (MESH:D019344), N6-methyladenosine (MESH:C010223)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12811398/full.md

---
Source: https://tomesphere.com/paper/PMC12811398